The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response

(1) Background: The first line of treatment for recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) has recently evolved with the approval of immunotherapies that target the anti-PD-1 immune checkpoint. However, only about 20% of the patients display a long-lasting objective tumor res...

Descripción completa

Detalles Bibliográficos
Autores principales: De Azevedo, Justine, Mourtada, Jana, Bour, Cyril, Devignot, Véronique, Schultz, Philippe, Borel, Christian, Pencreach, Erwan, Mellitzer, Georg, Gaiddon, Christian, Jung, Alain C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496761/
https://www.ncbi.nlm.nih.gov/pubmed/36139440
http://dx.doi.org/10.3390/cells11182866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496761/
https://www.ncbi.nlm.nih.gov/pubmed/36139440
http://dx.doi.org/10.3390/cells11182866

Ejemplares similares